Welcome to the international HTA database

Showing [24094 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2005	German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI)	Tumor-necrosis-factor alpha-antagonists in the treatment of rheumatoid arthritis - Economic efficiency
2003	The Swedish Council on Health Technology Assessment (SBU)	Tumor vaccination- early assessment briefs (Alert)
2024	Swiss Federal Office of Public Health (FOPH)	Tumor treating fields (TTFields) therapy for patients with glioblastoma multiforme
2011	HAYES, Inc.	Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS; Familial Hibernian Fever)
2002	Health Technology Advisory Committee (HTAC)	Tumescent liposuction
2001	HAYES, Inc.	Tumescent liposuction
2022	National Institute for Health and Care Excellence (NICE)	Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 786
2010	HAYES, Inc.	Tuberous Sclerosis Complex (TSC; Bourneville Disease)
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tuberculosis testing for correctional staff: diagnostic accuracy and guidelines
2001	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	TruScan
2008	NIHR Horizon Scanning Centre (NIHR HSC)	TroVax (MVA-5T4) for locally advanced or metastatic renal cell carcinoma â€“ with first line therapy
1997	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Troglitazone for Type II diabetes
2011	HAYES, Inc.	Trofile™ HIV tropism assay
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Triptorelin (Decapeptyl SR) for premenopausal women with early endocrine responsive breast cancer
2012	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triptans for migraine headaches: a review of clinical evidence on safety
2007	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triptans for acute migraine: comparative clinical effectiveness and cost-effectiveness
2000	British Columbia Office of Health Technology Assessment (BCOHTA)	Triple-marker screening in British Columbia: current practice, future options
2019	Penn Medicine Center for Evidence-based Practice (CEP)	Triple-lumen peripherally-inserted central catheters
2018	NIHR Health Technology Assessment programme	Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT
2025	Agency for Care Effectiveness (ACE)	Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2010	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triple therapy for moderate-to-severe chronic obstructive pulmonary disease
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triple therapy for hepatitis C in previous non-responders: a review of the clinical effectiveness and safety
2005	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Triple therapy for COPD
2021	Austrian Institute for Health Technology Assessment (AIHTA)	Triphasic biomaterial for augmentation of the osteoporotic femoral neck: systematic review
2021	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Triphasic biomaterial for augmentation of the osteoporotic femoral neck
2022	Swiss Federal Office of Public Health (FOPH)	Trimonthly vs. monthly use of bone-targeted agents in patients with bone metastases and multiple myeloma
2024	Swiss Federal Office of Public Health (FOPH)	Trikafta® for the treatment of patients with cystic fibrosis: an exploratory economic evaluation
2010	Adelaide Health Technology Assessment (AHTA)	Triggerfish continuous intraocular pressure monitoring system for the improved management of glaucoma patients
2002	Alberta Heritage Foundation for Medical Research (AHFMR)	Trigger point injections for non-malignant chronic pain
2009	HAYES, Inc.	Trigger point injections for myofascial pain
2013	HAYES, Inc.	Trigger point injections for myofascial pain
2005	Alberta Heritage Foundation for Medical Research (AHFMR)	Trigger point injections for chronic non-malignant musculoskeletal pain
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Trigeminal nerve stimulation to treat neuralgia
2022	National Institute for Health and Care Excellence (NICE)	Trifluridinetipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. NICE technology appraisal guidance 852
2024	National Institute for Health and Care Excellence (NICE)	Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments. NICE technology appraisal guidance 1008
2016	National Institute for Health and Care Excellence (NICE)	Trifluridine-tipiracil for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 405
2016	HAYES, Inc.	Trifluridine-tipiracil (Lonsurf) for refractory metastatic colorectal cancer
2009	HAYES, Inc.	TriFlange acetabular prosthesis for failed total hip arthroplasty with massive acetabular defects
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Trientine for treatment of Wilson's disease: clinical and cost-effectiveness, and safety
2020	The National Health Care Institute (ZIN, Zorginstituut Nederland)	Trientine tetrahydrochloride (Cuprior®) [for] the treatment of Wilson's disease
2004	Institute for Clinical Effectiveness and Health Policy (IECS)	Tridimensional radiotherapy for breast cancer
2013	Canadian Agency for Drugs and Technologies in Health (CADTH)	Tricyclic antidepressants, clonidine, venlafaxine, and modafinil for the treatment of attention-deficit/hyperactivity disorder in adults: a review of the clinical evidence
2024	Agency for Care Effectiveness (ACE)	Tricuspid transcatheter edge-to-edge repair system for symptomatic severe tricuspid regurgitation
2013	HAYES, Inc.	Triangle tilt surgery for treatment of obstetric brachial plexus injury
2019	NIHR Health Technology Assessment programme	Trial of Acute Femoral Fracture Fixation (TrAFFix). A feasibility study
2011	Canadian Agency for Drugs and Technologies in Health (CADTH)	Triaging patients from the emergency department to other medical centres: a review of the clinical evidence and guidelines
2021	Penn Medicine Center for Evidence-based Practice (CEP)	Triaging COVID-19 in the emergency department
2010	The Swedish Council on Health Technology Assessment (SBU)	Triage methods and patient flow processes at emergency departments
2018	The Regional Health Technology Assessment Centre (HTA-centrum)	Triage for prioritisation in the emergency department
2015	University of York	Triage and minimising crowding in emergency departments
2002	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Treprostinil
2020	National Institute for Health and Care Excellence (NICE)	Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant. NICE technology appraisal guidance 640
2024	National Institute for Health and Care Excellence (NICE)	Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal). NICE technology appraisal guidance 945
2023	Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)	Trends in utilisation of ultrasound by older Australians (2010-2019)
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Tremelimumab for unresectable pleural or peritoneal malignant mesothelioma – second and third line
2009	HAYES, Inc.	Trellis-8 Peripheral Infusion System (Bacchus Vascular Inc.) for deep vein thrombosis
2013	NIHR Horizon Scanning Centre (NIHR HSC)	Trebananib in combination with chemotherapy for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer
2021	Agency for Healthcare Research and Quality (AHRQ)	Treatments, technologies, and models for management of acute and chronic pain in people with a history of substance use disorder
2003	NIHR Health Technology Assessment programme	Treatments for spasticity and pain in multiple sclerosis: a systematic review
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatments for seasonal allergic rhinitis
2023	Norwegian Institute of Public Health (NIPH)	Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatments for patients with genotype 1 chronic hepatitis C: a review of evidence-based guidelines
2004	Quality Improvement Scotland (NHS QIS )	Treatments for opiate dependence
2010	VA Technology Assessment Program (VATAP)	Treatments for metastatic castrate-resistant prostate cancer
2017	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatments for locally advanced oropharyngeal cancer: a systematic review of clinical effectiveness and cost-effectiveness
2011	Agency for Healthcare Research and Quality (AHRQ)	Treatments for localized prostate cancer: systematic review to update the 2002 U.S. Preventive Services Task Force Recommendation.
2016	NIHR Health Technology Assessment programme	Treatments for hyperemesis gravidarum and nausea and vomiting in pregnancy: a systematic review and economic assessment
2015	Agency for Healthcare Research and Quality (AHRQ)	Treatments for Fibromyalgia in Adult Subgroups
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatments for fecal incontinence
2000	NIHR Health Technology Assessment programme	Treatments for fatigue in multiple sclerosis: a rapid and systematic review
2018	NIHR Health Technology Assessment programme	Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatments for constipation: a review of systematic reviews
2008	HAYES, Inc.	Treatments for binge eating disorder
2003	Canadian Coordinating Office for Health Technology Assessment (CCOHTA)	Treatments for benign prostatic hypertrophy
2017	Agency for Healthcare Research and Quality (AHRQ)	Treatments for basal cell and squamous cell carcinoma of the skin
2015	Agency for Healthcare Research and Quality (AHRQ)	Treatments for ankyloglossia and ankyloglossia with concomitant lip-tie
2021	Institute for Clinical and Economic Review (ICER)	Treatments for anemia in chronic kidney disease: effectiveness and value
2020	Agency for Healthcare Research and Quality (AHRQ)	Treatments for acute pain: a systematic review
2021	Agency for Healthcare Research and Quality (AHRQ)	Treatments and technologies supporting appropriate opioid tapers
2006	The Swedish Council on Health Technology Assessment (SBU)	Treatment with vitamin D and calcium
2006	HAYES, Inc.	Treatment with taxane agents (paclitaxel and docetaxel) for small cell lung cancer
2004	Institute for Clinical Effectiveness and Health Policy (IECS)	Treatment with pegylated interferon in hepatitis C
1997	The Swedish Council on Health Technology Assessment (SBU)	Treatment with neuroleptics: SBU summary and conclusions
2003	Institute for Clinical Effectiveness and Health Policy (IECS)	Treatment with interferon in hepatitis C
1994	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Treatment with biosynthetic growth hormone in Turner syndrome- primary research
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report
2005	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Treatment strategy for chronic Hepatitis C - systematic review
2012	Agency for Healthcare Research and Quality (AHRQ)	Treatment strategies for women with coronary artery disease
2005	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Treatment strategies for rheumatoid arthritis - primary research
2014	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment strategies for patients with renal colic: a review of the comparative clinical and cost-effectiveness
2013	Agency for Healthcare Research and Quality (AHRQ)	Treatment strategies for patients with peripheral artery disease
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatment strategies for patients with lower extremity chronic venous disease (LECVD)
2024	NIHR Health Technology Assessment programme	Treatment options for patients with pilonidal sinus disease: PITSTOP, a mixed-methods evaluation
1999	VA Technology Assessment Program (VATAP)	Treatment options for male erectile dysfunction: a systematic review of published studies of effectiveness part 1 and part 2
1999	Alberta Heritage Foundation for Medical Research (AHFMR)	Treatment options for acoustic neuroma
2005	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Treatment of varicose ulcer of the leg - primary research
2002	Alberta Heritage Foundation for Medical Research (AHFMR)	Treatment of thoracic insufficiency syndrome with the vertical expandable prosthetic titanium rib
2009	Institute for Clinical Effectiveness and Health Policy (IECS)	Treatment of symptomatic pelvic vascular malformations
2000	Healthcare Insurance Board/ College Voor Zorgverzekeringen (CVZ)	Treatment of suppurative otitis media in young children - primary research
2009	NIHR Health Technology Assessment programme	Treatment of severe ankle sprain: a pragmatic randomised controlled trial comparing the clinical effecitveness and cost-effectiveness of three types of mechanical ankle support with tubular bandage. The CAST trial